- The FDA will discuss the BLA for ALK and Merck's (MRK) ragweed sublingual allergy immunotherapy next month.
- The Ad Com is scheduled for January 28.
- MRK submitted the BLA in March. It was accepted in May.
- Evidence from what the companies call "extensive" clinical development support the tablets' ability to "reduce patients' allergy symptoms and their concomitant use of symptom-relieving medication."
Ad Com scheduled for Merck's ragweed immunotherapy
Dec 27 2013, 08:36 ET